---
run_id: halo-evidence-vs-diagnosis-validation-v8-substrate-workflow-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v8
benchmark_version: halo-evidence-vs-diagnosis-validation-v8-v1
model_condition: substrate_workflow
run_number: 5
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 503
prompt_source: condition packet (substrate_workflow) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a substrate preamble plus three reviewed source cards, then the frozen Advisor prompt - see run-packet.md
source_packet_sha256: 3cb2b1bbe627b1bc559da202163e4e65f7b4fe039ccf90688ace1e1316829fa4
condition_packet_sha256: 3cb2b1bbe627b1bc559da202163e4e65f7b4fe039ccf90688ace1e1316829fa4
output_file: model-outputs/substrate_workflow-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - substrate_workflow (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v8-v1`, condition `substrate_workflow`, run 5 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 503, on the frozen condition packet.

## Output

I recommend that you advise the CEO to commit to the **targeted evidence pass**.

### Reasoning
The "upbeat story" currently being prepared for the board is a textbook example of the **halo effect** (BK-0048-card-001). Six months ago, the team's behavior was described as "bespoke" and "reactive"; today, the same behaviors are called "customer-obsessed" and "disciplined." This shift in trait assessment is not based on independent evidence of improved discipline, but is a reflection of the recent revenue bump. Because the performance signal (NRR and renewals) is positive, leadership is retrospectively re-coding the team's attributes to fit that success.

However, the underlying evidence suggests that this performance signal is a mirage:
1. **Vanity Metrics vs. Validated Learning:** Following the framework of **validated learning** (BK-0007-card-001), the current "progress" is measured by execution targets (feature shipment and NRR) rather than empirical evidence of customer value. The 18% revenue increase is largely artificial (72% tied to discounts), and the 44% usage increase is skewed by a small group of champions. The critical metric—front-line reviewer retention—is a dismal 31%.
2. **Lack of a Strategic Diagnosis:** Any move to "scale broadly" or "narrow to regulated workflows" at this stage would be a failure of the **strategy kernel** (BK-0001-card-001). A real strategy requires a *diagnosis*—an account of the challenge that picks out the factors that actually matter. Currently, the company does not know if the primary challenge is "auditor explainability" (the insurance case), "front-line utility" (the 31% retention case), or "artificial incentive structures" (the discount case).

Scaling now would be "scaling a guess," while pivoting to regulated workflows would be a "leap of faith" without a verified diagnosis. The evidence pass is the only option that treats the current situation as a hypothesis to be tested rather than a victory to be scaled.

### The Strongest Reason Against This Recommendation
**Loss of perceived momentum and political capital.** The board and sales leadership are currently experiencing the "halo" of success. Pausing discounts and slowing the rollout to instrument behavior will be perceived as "braking" during a win. In a high-pressure B2B environment, the CEO may fear that admitting the revenue bump is artificial—or that the "customer-obsessed" label is a delusion—will damage the team's credibility or jeopardize the budget lock.

### Evidence That Would Change My Mind
I would change this recommendation if you could provide evidence that the **revenue bump is organic and decoupled from the discounts**. Specifically, if the 18% expansion revenue was driven by customers paying *more* for the value of Review Assist without the incentive of a six-month discount, it would suggest the product has found a genuine market wedge. In that case, the "performance signal" would be an independent validator of value rather than a distorting lens, making the "scale broadly" option a viable strategic move.
